Alfuzosin Hydrochloride
Product Images NDC 43353-746

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 43353-746). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 10mg (43353 746 30)

This is a medication called Alfuzosin HCI ER, which comes in a pack of 30 tablets each, with a strength of 10mg. The NOC# 353074630 could be a reference number for the medication.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Alfuzosin Hydrochloride Structural Formula (A9ef5385 3416 452b 97ac Cac1b1bdb97f 01)

FDA Label Image

Figure 1: Mean (sem) Alfuzosin Plasma Concentration-time Profiles After A Single Administration Of Alfuzosin Hydrochloride Extended-release Tablets 10 mg To Eight Healthy Middle-aged Male Volunteers In Fed And Fasted States (A9ef5385 3416 452b 97ac Cac1b1bdb97f 02)

This appears to be a graph showing the plasma concentration of Alfuzosin over time (in hours) for both fed and fasted conditions. The y-axis measures concentration in ng/mL, while the x-axis represents time in hours. It may be part of a study or research on the effects of food on the pharmacokinetics of Alfuzosin.*

FDA Label Image

Figure 2: Mean Change From Baseline In Ipss Total Symptom Score: Trial 1 (A9ef5385 3416 452b 97ac Cac1b1bdb97f 03)

FDA Label Image

Figure 3: Mean Change From Baseline In Ipss Total Symptom Score: Trial 2 (A9ef5385 3416 452b 97ac Cac1b1bdb97f 04)

FDA Label Image

Figure 4: Mean Change From Baseline In Ipss Total Symptom Score: Trial 3 (A9ef5385 3416 452b 97ac Cac1b1bdb97f 05)

FDA Label Image

Figure 5: Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 1 (A9ef5385 3416 452b 97ac Cac1b1bdb97f 06)

FDA Label Image

Figure 6: Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 2 (A9ef5385 3416 452b 97ac Cac1b1bdb97f 07)

This appears to be a statistical analysis of the mean change in milliliters (mLTs) for two groups receiving different treatments - a placebo group and a group receiving Alfuzosin HOI ER. There were 147 participants in the placebo group and 136 in the Alfuzosin group. The data was collected over 56 days of treatment and there was a statistically significant difference between the two groups (p<0.05). No further information is available.*

FDA Label Image

Figure 7: Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 3 (A9ef5385 3416 452b 97ac Cac1b1bdb97f 08)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.